Evaluating Toripalimab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi .
Coherus BioSciences, Inc.February 1, 2021 GMT
- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody
- First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation
- Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential
- Conference call at 8:00 am Eastern Time today
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced a collaboration with Shanghai Junshi Biosciences, Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the Uni ....

United States , San Francisco , Denny Lanfear , Jonathan Lanfear , Sunitinib Monotherapy , Hart Scott Rodino , Junshi Bioscience , Eli Lilly , Mcdavid Stilwell , Junshi Biosciences , Coherus Biosciences Inc , Ropes Gray , Committee On Foreign Investment , China National Medical Products Administration , Abbvie Inc , Co Ltd Junshi Biosciences , Regeneron Pharmaceuticals Inc , Institute Of Microbiology Chinese Academy Science , Drug Administration , Lanfear Advisors , Genentech Inc , China National Healthcare Security Administration , Exchange Commission , National Reimbursement Drug List , Eastern Time , Shanghai Junshi Biosciences ,